Regeneron Pharmaceuticals Inc. (REGN) Company Profile
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions in the United States. The company?s commercial product includes ARCALYST (rilonacept) injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. Its products under Phase III clinical development stage consist of VEGF Trap-Eye, an aflibercept ophthalmic solution developed using intraocular delivery for the treatment of serious eye diseases; ARCALYST for the prevention of gout flares in patients initiating uric acid-lowering treatment; and Aflibercept (VEGF Trap), which is developed in oncology. The company?s earlier stage clinical programs include various human antibodies, such as REGN727 for low-density lipoprotein cholesterol reduction, REGN88 for rheumatoid arthritis and ankylosing spondylitis; REGN668 for atopic dermatitis and asthma; REGN421 and REGN910 for oncology; REGN475 for the treatment of pain; and REGN728 and REGN846. It also conducts preclinical research programs in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, cardiovascular diseases, and infectious diseases. The company distributes its products through third party service providers. It has strategic collaboration with sanofi-aventis Group to discover, develop, and commercialize human monoclonal antibodies; and Bayer HealthCare LLC to develop and commercialize VEGF Trap. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is based in Tarrytown, New York.
News about REGN
The Trump Administration's Squeeze On Affordable Health Insurance For 50- To 64-Year-Olds
&l;p&g;&l;img class=&q;dam-image getty size-large wp-image-860674444&q; src=&q;https://specials-images.forbesimg.com/dam/imageserve/860674444/960x0.jpg?fit=scale&q; data-height=&q;640&q; data-width=&q;960&q;&g; U.S. President Donald Trump speaks as S...Read More>>>
5 Warren Buffett Principles to Remember in a Volatile Stock Market
Over the past week, the Dow Jones Industrial Average has fallen by nearly 700 points, mainly fueled by fears of a global trade war. And there's no reason to think the volatility will subside anytime soon. However, instead of panicking, it's important...Read More>>>
Benzinga Pro's 5 Stocks To Watch Today
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user! JD.Com Inc(ADR) (NASDAQ: JD) was trading higher by more than 5 percent ahead of Monday's opening...Read More>>>
Lupin gains 3% on USFDA approval for pregnancy prevention tablets
Shares of Lupin gained more than 3 percent intraday Thursday as company received USFDA approval for pregnancy prevention tablets.The company has received final approval for its Drospirenone, Ethinyl Estradiol, Levomefolate Calcium Tablets and Levomef...Read More>>>
Should CRISPR Stock Investors Worry About Cancer?
Stocks tied to CRISPR technology took a hit on Monday after Swedish scientists highlighted a disturbing link between the gene-editing technology and cancer. Sooner or later, just about everything gets accused of causing cancer, but the latest allegat...Read More>>>